Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Nationwide Children's Hospital
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
University of Virginia
Bayer
National Cancer Institute (NCI)
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
New York Medical College
Children's National Research Institute
MacroGenics
Children's Oncology Group
Barbara Ann Karmanos Cancer Institute
Emory University
Emory University
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Nationwide Children's Hospital
Masonic Cancer Center, University of Minnesota
New York Medical College
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Michigan Rogel Cancer Center
Children's Oncology Group
National Institutes of Health Clinical Center (CC)